GSK plc (GSK) Goldman Sachs 44th Annual Global Healthcare Conference (Transcript)

Summary of GSK plc Conference Call Company Overview - Company: GSK plc (NYSE:GSK) - Event: Goldman Sachs 44th Annual Global Healthcare Conference Call - Date: June 13, 2023 - Participants: Tony Wood (Chief Scientific Officer), Chris Shibutani (Goldman Sachs) Key Points Industry Focus - GSK is focusing on several therapeutic areas: infectious diseases, HIV, immunology, respiratory, and oncology [5][6][9] R&D Strategy - GSK has identified a strong position in vaccines, particularly in protein subunit vaccines and adjuvants, and is investing in technologies like structure-based vaccinology and mRNA [6][7][8] - The acquisition of Affinivax is aimed at entering the pneumococcal vaccine market, which is the second largest after COVID vaccines [7] - GSK is developing capabilities in mRNA technology through collaboration with CureVac, focusing on high-dose flu and COVID vaccines [8] Vaccine Development - GSK is competitive in the high-dose flu and COVID vaccine market but acknowledges being slightly behind in timing compared to competitors like Moderna [11] - The company is conducting multivalent flu studies to establish a presence in the high-dose flu market [11] - GSK's RSV vaccine has shown a 94% efficacy in at-risk populations, with ongoing studies to expand data for older adults [15][17] HIV Treatment and PrEP - GSK's strategy in HIV focuses on long-acting regimens and the integration of cabotegravir, which has strong resistance characteristics [25][26] - The market for PrEP is underpenetrated, with only 25% of eligible patients receiving treatment in the U.S. [29] Competitive Landscape - GSK's Shingrix vaccine offers 10-12 years of protection, presenting a high barrier for new entrants [32] - In the meningococcal vaccine space, GSK emphasizes the importance of vaccine efficacy and strain coverage compared to competitors [34] Antibiotics and Oncology - GSK continues to explore opportunities in antibiotics despite challenges, focusing on acquisitions that can make economic sense [39] - Oncology remains an area of interest, with ongoing evaluations of existing products and potential new deals [41] Future Outlook - GSK is preparing for the 2023 vaccine season and is confident in its manufacturing capabilities [19] - The company is exploring expansion into different age groups for its vaccines but does not plan to revisit maternal vaccines at this time [21] Additional Insights - GSK is focused on the balance between vaccine efficacy and convenience in the context of combination vaccines [23] - The company is monitoring the competitive landscape closely, particularly in the context of emerging technologies and products from competitors [41] This summary encapsulates the critical insights from the GSK conference call, highlighting the company's strategic focus, competitive positioning, and future outlook in the healthcare industry.